标题:A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy
作者:Mu, Weiwei; Chu, Qihui; Liu, Yongjun; Zhang, Na
作者机构:[Mu, Weiwei; Chu, Qihui; Liu, Yongjun; Zhang, Na] Shandong Univ, Cheeloo Coll Med, Sch Pharmaceut Sci, Key Lab Chem Biol,Minist Educ,Dept Pharmaceut, 更多
通讯作者:Zhang, N(zhangnancy9@sdu.edu.cn)
通讯作者地址:Zhang, N (corresponding author), Shandong Univ, Cheeloo Coll Med, Sch Pharmaceut Sci, Key Lab Chem Biol,Minist Educ,Dept Pharmaceut, 44 Wenhuaxi Rd, J 更多
来源:NANO-MICRO LETTERS
出版年:2020
卷:12
期:1
DOI:10.1007/s40820-020-00482-6
关键词:Cancer therapy; Chemotherapy; Immunotherapy; Chemoimmunotherapy;; Nano-based drug delivery system
摘要:Although notable progress has been made on novel cancer treatments, the overall survival rate and therapeutic effects are still unsatisfactory for cancer patients. Chemoimmunotherapy, combining chemotherapeutics and immunotherapeutic drugs, has emerged as a promising approach for cancer treatment, with the advantages of cooperating two kinds of treatment mechanism, reducing the dosage of the drug and enhancing therapeutic effect. Moreover, nano-based drug delivery system (NDDS) was applied to encapsulate chemotherapeutic agents and exhibited outstanding properties such as targeted delivery, tumor microenvironment response and site-specific release. Several nanocarriers have been approved in clinical cancer chemotherapy and showed significant improvement in therapeutic efficiency compared with traditional formulations, such as liposomes (Doxil(R), Lipusu(R)), nanoparticles (Abraxane(R)) and micelles (Genexol-PM(R)). The applications of NDDS to chemoimmunotherapy would be a powerful strategy for future cancer treatment, which could greatly enhance the therapeutic efficacy, reduce the side effects and optimize the clinical outcomes of cancer patients. Herein, the current approaches of cancer immunotherapy and chemoimmunotherapy were discussed, and recent advances of NDDS applied for chemoimmunotherapy were further reviewed.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087406045&doi=10.1007%2fs40820-020-00482-6&partnerID=40&md5=30eaae2534886545b4b976875344cc72
TOP